Infuseon Therapeutics inked a deal this week with OncoSynergy to evaluate a glioblastoma therapeutic with the Cleveland Clinic spinout’s novel delivery device.
The alliance hopes to demonstrate proof-of-concept that OncoSynergy’s candidate can be successfully delivered directly to a patient’s brain using the device in a Phase I glioblastoma trial.
Get the full story at our sister site, Drug Delivery Business News.
The post Cleveland Clinic spinout Infuseon inks deal with OncoSynergy appeared first on MassDevice.
from MassDevice http://ift.tt/2sBLW3A
Cap comentari:
Publica un comentari a l'entrada